These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2275891)

  • 21. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
    J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sotalol for atrial tachycardias after surgery for congenital heart disease.
    Beaufort-Krol GC; Bink-Boelkens MT
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2125-9. PubMed ID: 9272523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.
    Kehoe RF; Zheutlin TA; Dunnington CS; Mattioni TA; Yu G; Spangenberg RB
    Am J Cardiol; 1990 Jan; 65(2):58A-64A; discussion 65A-66A. PubMed ID: 2294689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of oral sotalol in early infancy.
    Tipple M; Sandor G
    Pacing Clin Electrophysiol; 1991 Nov; 14(11 Pt 2):2062-5. PubMed ID: 1721225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.
    Kopelman HA; Woosley RL; Lee JT; Roden DM; Echt DS
    Am J Cardiol; 1988 May; 61(13):1006-11. PubMed ID: 3284316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Sotalol and torsades de pointes ventricular tachycardia].
    Petersen HH; Sandøe E
    Ugeskr Laeger; 1996 May; 158(19):2711-6. PubMed ID: 8744073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual chamber rate responsive pacing to allow sotalol therapy for ventricular tachycardia.
    Horrigan MC; Davis MJ; May C; Smith P
    Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 2):2108-10. PubMed ID: 1279608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antiarrhythmic effects of d-sotalol.
    Schwartz J; Crocker K; Wynn J; Somberg JC
    Am Heart J; 1987 Sep; 114(3):539-44. PubMed ID: 3630894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
    Antz M; Cappato R; Kuck KH
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):627-35. PubMed ID: 8569226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of oral sotalol for treatment of pediatric arrhythmias.
    Maragnès P; Tipple M; Fournier A
    Am J Cardiol; 1992 Mar; 69(8):751-4. PubMed ID: 1546649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Results of oral sotalol therapy in children with supraventricular and ventricular arrhythmias].
    Paul T; Lehmann C; Pfammatter JP; Kallfelz HC
    Z Kardiol; 1994 Dec; 83(12):891-7. PubMed ID: 7531374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction.
    Kassotis J; Sauberman RB; Cabo C; Wit AL; Coromilas J
    J Cardiovasc Electrophysiol; 2003 Nov; 14(11):1233-44. PubMed ID: 14678141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
    Lee SD; Newman D; Ham M; Dorian P
    J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia.
    Senges J; Lengfelder W; Jauernig R; Czygan E; Brachmann J; Rizos I; Cobbe S; Kübler W
    Circulation; 1984 Mar; 69(3):577-84. PubMed ID: 6692518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Electrophysiologic effect of sotalol in supraventricular tachycardias].
    Borggrefe M; Breithardt G
    Z Kardiol; 1985 Sep; 74(9):506-11. PubMed ID: 4060828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents.
    Nademanee K; Singh BN
    Am J Cardiol; 1990 Jan; 65(2):53A-57A; discussion 65A-66A. PubMed ID: 2403735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
    Boriani G; Lubinski A; Capucci A; Niederle R; Kornacewicz-Jack Z; Wnuk-Wojnar AM; Borggrefe M; Brachmann J; Biffi M; Butrous GS;
    Eur Heart J; 2001 Dec; 22(23):2180-91. PubMed ID: 11913480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol.
    Leite LR; Fenelon G; Simoes A; Silva GG; Friedman PA; de Paola AA
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):567-73. PubMed ID: 12875414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.